| 1 |
Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.Nature,2003,421(6924):744-748.
|
| 2 |
Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a patho genie T cell population that induces autoimmune inflammation. Exp Med,2005,201(2):233-240.
|
| 3 |
Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cellsregulates tissue in?ammation by producing interleukin 17. Nat Immunol,2005,6(11):1133-1141.
|
| 4 |
Harrington LE,Hatton RD,Mangan PR,et al.Interleukin 17-producing CD4+ effector T cells Develop via a lineage distinct from the T helper type 1 and 2 lineages.Nat.Immunol,2005,6(11):1123-1132.
|
| 5 |
Aggarwal S,Ghilardi N,Xie MH,et al.Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17.J Biol Chem,2003,278(3):1910-1914.
|
| 6 |
Thakker P,Leach MW,Kuang W,et al.IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis.J Immunol,2007,178(4):2589-2598.
|
| 7 |
Sutton C,Brereton C,Keogh B,et al.A crucial role for interleukin(IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis.JEM,2006,203(7):1685-1691.
|
| 8 |
Kimura A, Naka T, Kishimoto T.IL-6-dependent and independent pathways in the development of interleukin 17-producing T helper cells.Proc Natl Acad Sci USA,2007,104(29):12099-12104.
|
| 9 |
Hoeve MA, Savage ND, de Boer T, et al. Divergent effects 0f IL-12 and IL-23 on the production of IL-17 by human T cells. Eur J lmmunol,2006,36(3):661-670.
|
| 10 |
Chen Y, Langrish Cl, McKenzie B, et al. Anti IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis.J Clin Invest,2006,116(5):1317-1326.
|
| 11 |
Veldhoen M, Hocking RJ, Flavell RA, et al. Signals medated by transforming growth factor beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat Immunol,2006,7(11):1151-1156.
|
| 12 |
Bettelli E, Carrier Y, GaoWd, et al. Reciprocal developmental pathways for the generation of pathogenic effector Thl7 and regulatory cells.Nature,2006,441(7090):235-238.
|
| 13 |
Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgamma directs the dif -ferentiation program of proinflammatory IL-17 T helper cells.Cell,2006,126(6):1121-1133.
|
| 14 |
Rangachari M,Mauermann N,Marty RR,et al.T-bet negatively regulates Autoimmune myocarditis by suppressing local production of interleukin 17.Exp Med,2006,203(8):2009-2019.
|
| 15 |
Loong CC, Hsieh HG, Lui WY, et al. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection.J Pathol,2002,197(3):322-332.
|
| 16 |
Li J, Simeoni E, Fleury S, et al. Gene transfer of soluble interleukin-17 receptor prolongs cardiac allograft survival in a rat model. Eur J Cardiothorac Surg,2006,29(5):779-783.
|
| 17 |
Ciree A,Michel L,Camilleri-Broet S,et al.Expression and activity of IL-17 in cutaneous T-cell lymphomas(mycosis fungoides and Sezary syndrome).Int J Cancer,2004,112(1):113-120.
|
| 18 |
Wrobel T,Mazur G,Jazwiec B,et al.Interleukin-17 in acute myeloid leukemia.Cell Mol Med,2003,7(4):472-474.
|
| 19 |
Numasaki M, Watanabe M, Suzuki T, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human nonsmall cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.J Immunol,2005,175(9):6177-6189.
|
| 20 |
Hwang SY,Kim HY. Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. Mol Cells,2005,19(2):180-184.
|
| 21 |
Ohsugi Y. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull,2007,30(11):2001-2006.
|